Apple and Masimo's patent and trade secret dispute has intensified through lawsuits as Apple defends its innovations and ...

The consensus rating for Masimo is Buy, based on 2 analyst ratings. With an average one-year price target of $167.5, there's a potential 16.14% upside.

Beyond analysts' top -and-bottom-line estimates for Masimo (MASI), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ...

Buying $1000 In MASI: If an investor had bought $1000 of MASI stock 10 years ago, it would be worth $5,655.84 today based on a price of $144.22 for MASI at the time of writing.

Roots Community Health has sued 12 other firms, including GE Healthcare, CVS and Walgreens, and called for manufacturers and ...

QSC LLC, which specializes in audio, visual and control systems, has agreed to be acquired by Atlanta-based Acuity Brands ...

IRADIMED CORPORATION (the “Company”) (NASDAQ: IRMD) was recently named one of Fortune’s 100 Fastest Growing Companies for 2024. Iradimed is a leader in the development of innovative magnetic resonance ...

Becton Dickinson and Company BDX, popularly known as BD, is scheduled to report fourth-quarter fiscal 2024 results on Nov. 7, ...

Cencora COR is slated to report fiscal fourth-quarter 2024 results on Nov. 06, before market open. In the last reported ...

The official holiday 2024 sale at B&H provides bargain hunters with steep savings on MacBooks, desktop Macs, podcasting gear ...

Incyte filed a lawsuit to try to block the launch of Leqselvi, claiming that the drug infringed a US patent (No. 9,662,335) ...

The global non-invasive respiratory monitoring market is poised for substantial growth, projected to increase from an estimated valuation of USD 8.4 Billion in 2023 to USD 15.0 Billion by 2033, at a ...